Libet's Experiment, Its Replicability, Validity and Clinical Potential

Total Page:16

File Type:pdf, Size:1020Kb

Libet's Experiment, Its Replicability, Validity and Clinical Potential Palacký University Olomouc Faculty of Arts Department of Psychology Libet's experiment, its replicability, validity and clinical potential Libetův experiment, jeho replikabilita, validita a klinický potenciál Dissertation thesis Author: Mgr. Tomáš Dominik Supervisor: PhDr. Mgr. Roman Procházka, Ph.D. Olomouc 2019 Words of thanks Within the circles of experimental and cognitive psychologists, Libet’s experiment is sometimes dubbed “the experiment which started a thousand careers”. I sincerely hope that this thesis will add one more to that thousand. Present dissertation thesis reflects more than three years of research I, together with my colleagues, have conducted in this field. Since the beginning of my undergraduate studies, I was intrigued by the question of free will, but it took me four years to take the courage to tackle Libet’s experiment because I viewed it as something far beyond my capabilities. Nonetheless, thanks to encouragement of my supervisors and thanks to my luck of meeting the right researchers sharing my interests, I can now address some questions persisting in the “libetian” discussions to this day. I would like to express my gratitude to all the people who allowed me to conduct this research, namely: • Roman Procházka for his willingness to supervise this thesis, to share his clinical expertise with me and to read the manuscript of this thesis. • Martin Zielina for his supervision of my previous master thesis, for the stimulating discussions we had throughout my Ph.D. studies and for reading the manuscript of this thesis. • Daniel Dostál for mental stimulation, his inspiring zeal for cognitive psychology and data science, for help with data analyses and for reading the manuscript of this thesis. • Daniel Dostál, Martin Zielina, Roman Procházka, Jan Šmahaj and Zuzana Vaculčíková Sedláčková for cooperating on our projects and papers. • Barbora Sedláková, Markéta Zajícová and others who allowed me to collect data within their institutions. • Michal Kluka for language help with Studies 1 and 2. • Miroslav Kuba and Jan Kremláček for consultations pertaining the ERP analyses. • Patrick Haggard, Axel Cleeremans and all the members of their labs for hosting me and encouraging me to join the flow of current neuroscience and cognitive sciences. • The Department of Psychology, Faculty of Arts at Palacký University Olomouc, and especially its head Matúš Šucha, for creating an ideal academical working environment. • My family and especially my girlfriend, Jana Mišelnická, for much needed support. Acknowledgment This thesis was supported by Palacký University Olomouc, Czech Republic [IGA FF_2015_022, IGA FF_2017_021]. I hereby proclaim that I have written this dissertation thesis named “Libet's experiment, its replicability, validity and clinical potential” by myself, under the supervision of PhDr. Mgr. Roman Procházka, Ph.D. and using only cited literature. Studies 1 and 2 presented in this thesis were published and are used with consent of all co-authors (see Appendix 3). Místopřísežně prohlašuji, že jsem dizertační práci na téma: „Libetův experiment, jeho replikabilita, validita a klinický potenciál“ vypracoval samostatně pod odborným dohledem PhDr. Mgr. Romana Procházky, Ph.D., a uvedl jsem všechny použité podklady a literaturu. Studie 1 a 2 prezentované v této práci byly již publikovány a jsou použity se souhlasem všech spoluautorů (viz Appendix 3). In Olomouc on the 18th June 2019 Signature ................................ Table of contents Introduction ............................................................................................................................ 6 Theoretical part: History of Libet’s experiment, its methods and discussions ...................... 8 1 Historical background ..................................................................................................... 8 2 Methods and results of Libet’s experiment ................................................................... 10 2.1 Libet’s sample ........................................................................................................ 12 2.2 Libet’s equipment .................................................................................................. 13 2.2.1 Electroencephalographic recordings (EEG) .................................................... 13 2.2.2 Electromyographic recordings (EMG) ............................................................ 14 2.2.3 Experimental clock ......................................................................................... 15 2.2.4 Skin stimulation .............................................................................................. 16 2.3 Tasks in Libet’s experiment ................................................................................... 16 2.3.1 Self-initiated voluntary acts (M and W series) ............................................... 17 2.3.2 Pre-set motor acts (P and Pv series) ................................................................ 18 2.3.3 Skin stimuli at unknown times (S series) ........................................................ 19 2.3.4 Skin stimuli at pre-set times (Sp series) .......................................................... 19 2.4 Libet’s results ......................................................................................................... 20 2.4.1 Results of neural data analyses ....................................................................... 21 2.4.2 Results of introspective reports analyses ........................................................ 24 2.5 Libet’s conclusions ................................................................................................ 25 3 Critique and discussions of Libet’s experiment ............................................................ 29 3.1 Discussions of the intention to move (W reports) .................................................. 29 3.2 Discussions of the reports of the movement onset (M reports) ............................. 34 3.3 Discussions of the reports of skin stimulus (S reports) .......................................... 36 3.4 Discussions of the readiness potential (RP) ........................................................... 38 3.5 Sense of agency concept ........................................................................................ 47 Empirical part: Libet’s experiment validity, replicability and clinical potential ................. 51 4 Study 1: Validity of measuring the urge to move ......................................................... 51 4.1 Introduction ............................................................................................................ 51 4.2 Materials and methods ........................................................................................... 53 4.2.1 Participants ...................................................................................................... 53 4.2.2 Technical equipment ....................................................................................... 54 4.2.3 Experimental procedure and design ................................................................ 55 4.2.4 Variables ......................................................................................................... 56 4.2.5 Data analysis ................................................................................................... 56 4.3 Results .................................................................................................................... 59 4.4 Discussion .............................................................................................................. 60 4.5 Limitations and Recommendations ....................................................................... 64 4.6 Conclusions ............................................................................................................ 65 5 Study 2: A complex replication of Libet’s experiment ................................................. 66 5.1 Introduction ............................................................................................................ 66 5.2 Materials and methods ........................................................................................... 68 5.2.1 Participants ...................................................................................................... 68 5.2.2 Introspective data measurements .................................................................... 68 5.2.3 Recordings and skin stimulation ..................................................................... 70 5.2.4 Types of the experimental tasks ...................................................................... 72 5.2.5 Progression of the experiment ........................................................................ 75 5.2.6 Data analyses .................................................................................................. 80 5.3 Results .................................................................................................................... 84 5.3.1 EMG onset timing ........................................................................................... 84 5.3.2 Introspective impressions timing .................................................................... 86 5.3.3 Event-related potentials occurrence and timing .............................................. 91 5.3.4 Interindividual differences ............................................................................ 100 5.3.5 Series-specific effects
Recommended publications
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • In February 2013, Glaxosmithkline (GSK) Announced a Commitment To
    In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The following guiding principles have been applied to the disclosure: Information will be excluded in order to protect the privacy of patients and all named persons associated with the study Patient data listings will be completely removed* to protect patient privacy. Anonymized data from each patient may be made available subject to an approved research proposal. For further information please see the Patient Level Data section of the GSK Clincal Study Register. Aggregate data will be included; with any direct reference to individual patients excluded *Complete removal of patient data listings may mean that page numbers are no longer consecutively numbered CONFIDENTIAL GM2004/00056/00GM2004/00056/00 SAM40040SAM40040 The GlaxoSmithKline group of companies A twenty-four week, randomised, double-dummy, double-blind, parallel group study to compare the occurrence of exacerbations between SERETIDE DISKUS 50/250µg 1 inhalation bd and formoterol/budesonide Breath-Actuated Dry Powder Inhaler 4.5/160µg 2 inhalations bd in subjects with moderate to severe asthma. Clinical Study Report for Study SAM40040 (Development Phase IV) Document Number: GM2004/00056/00 Compound Number: CCI18781/ GR33343 Investigational Product: SERETIDE Generic Drug Name: salmeterol/fluticasone propionate combination Indication Studied: Asthma Initiation Date: 26 Nov 2001 Completion Date: 13 Jan 2003 Early Termination Date: N/A Date of Report: August 2004 Sponsor Signatory: (and Medical Officer) Vice President European Clinical Respiratory Medicines Development Centre This study was performed in compliance with Good Clinical Practices including the archiving of essential documents.
    [Show full text]
  • Moderní Antihistaminika V Léčbě Alergie – Současné Trendy V Symptomatické Terapii Alergických Onemocnění
    100 Hlavní téma Moderní antihistaminika v léčbě alergie – současné trendy v symptomatické terapii alergických onemocnění Jaroslava Braunová, Mojmír Račanský Oddělení alergologie a klinické imunologie FNOL, Ústav imunologie UP Olomouc Alergická onemocnění jsou problémem současné medicíny. Nejde o pouhé projevy sezónní rýmy, s nimiž se do jisté míry setkal snad každý, ale také o závažné stavy, jako je anafylakticky šok a exacerbace bronchiálního astmatu. Nezanedbatelnou kapitolu tvoří problematika různých kožních projevů přecitlivělosti. Vždy však působí postiženému značné nepříjemnosti. Spolu s rostoucí incidencí těchto alergolo- gických diagnóz pochopitelně stoupá i poptávka po jejich účinné léčbě. Za kauzální léčbu považujeme alergenovou imunoterapii (AIT). Ta však není indikována pro všechny pacienty a všechny alergologické diagnózy. Vyžaduje vysokou compliance ze strany nemocného, přesné určení spouštěče alergické reakce u daného pacienta a existenci dostupného standardizovaného alergenu. Symptomatická terapie antihistaminiky představuje jednu ze zásadních možností ovlivnění rozvoje alergické reakce přímo na periferním histaminovém receptoru H1. Klíčová slova: alergie, symptomatická terapie, antihistaminika, alergický zánět. Modern antihistamines in treating allergies: current trends in symptomatic therapy of allergic conditions Allergic diseases are a serious problem in modern medicine. It is not only a question of pollinosis, but also of other allergic diseases such as bronchial asthma, atopic dermatitis, urticaria, angioedema or
    [Show full text]
  • Obecná Alergologie, Alergie - Pojem
    12.02.2017 Obecná alergologie, Alergie - pojem (alergie, „nealergie“, alergeny, léčba neadekvátní reakce imunitního systému typu zánětu alergií a alergické stavy) na jinak neškodnou cizorodou látku (alergen), má s přihlédnutím k dětskému věku objektivní i subjektivní složku: - objektivně jsou známky poškození některých orgánů (sliznice nosu, spojivky, kůže, bronchy, ..) - subjektivně jsou nepříjemně vnímané poruchy funkce takto postižených orgánů Alergik = pacient s klinickými příznaky reakce přecitlivosti navozené imunolog.mechanismy. MUDr.Jiří NEVRLKA Poliklinika Zahradníkova 2/8 BRNO ambulance pro alergologii a klinickou imunologii Alergie pozitivita v testech na alergeny !! Alergie - pojem Alergie - pojem imunopatologické reakce „nepravé alergie a pseudoalergie“ časný typ Reakce I.typu - mediovaná protilátkami IgE, • IgE non dependentní alergie (pozdní typ) - vyjádřena u osob s atopickou reaktivitou Alergolog - reakce nezprostředkovaná IgE, ale Ag-specif.T-lymfocyty - nejčastější typ alergie (alergie v užším smyslu) navazující na IgE mechanismus .. např. potraviny, alergie na lepek - inhalační alergie, alergie hmyzí jed, anafylaxe, (atopická dermatitida).. dominantní mechanismus .. např. kontaktní alergeny, léky, celiakie Reakce II.typu - mediovaná non IgE protilátkami - cytotoxické protilátky, např. transfuzní reakce x blokující protilátky, např. • Zkřížená reaktivita: myastenia gravis x stimulační protilátky, např. Graves-Basedowova choroba - reakce na antigeny strukturálně podobné reálnému alergenu Reakce III.typu – mediovaná
    [Show full text]
  • Azelastine Hydrochloride
    568 Antihistamines been withdrawn from the market in most countries because of the Preparations treatment of non-allergic rhinitis in adults and children risk of adverse effects. USP 31: Azatadine Maleate Tablets. aged 12 years and over. The dose is 2 sprays into each Astemizole has been given in an oral dose of 10 mg once daily, Proprietary Preparations (details are given in Part 3) nostril twice daily. In the treatment of conjunctivitis, or 5 mg daily in children aged 6 to 12 years. These doses must Austral.: Zadine; Canad.: Optimine; Hong Kong: Zadine†; Malaysia: azelastine is licensed in the UK for the treatment of not be exceeded because of the risk of cardiac arrhythmias with Zadine†; Mex.: Idulamine†; NZ: Zadine†; Singapore: Zadine†; Spain: seasonal allergic conjunctivitis in adults and children higher doses. Lergocil. aged 4 years and over and for the treatment of perenni- The active metabolite of astemizole, tecastemizole (norastemi- Multi-ingredient: Braz.: Cedrin; Canad.: Trinalin; Mex.: Trinalin†; al allergic conjunctivitis in adults and children aged 12 zole) has been investigated for the treatment of allergic rhinitis. Spain: Atiramin; Idulanex; USA: Rynatan†; Trinalin†. years and over. In the USA, it is licensed for the treat- Preparations ment of allergic conjunctivitis in adults and children USP 31: Astemizole Tablets. aged 3 years and over. Regardless of the age and indi- Azelastine Hydrochloride cation, a 0.05% solution is instilled into each eye twice Proprietary Preparations (details are given in Part 3) (BANM, USAN, rINNM) daily; this may be increased to four times daily in se- Arg.: Alermizol†; Astezol†; Cezane†; Mudantil†; Cz.: Hismanal†; Gr.: Mibiron†; Tulipe-R†; Tyrenol†; Waruzol†; India: Astizole; Stemiz†; Mex.: A-5610 (azelastine or azelastine hydrochloride); Atselastiinihy- vere conditions.
    [Show full text]
  • Prezentace Aplikace Powerpoint
    Immunostimulation and Immunomodulation - Vaccination, Biological Treatment, Current Possibilities of Immunological Intervention Mgr. Michal Křupka, Ph.D. Pharmacotherapy in immunology Allergy therapy - antihistamines, cromoglycans, corticoids, local alpha and betamimetics, biological therapy, specific immunotherapy Immunosuppression - NSAIDs, corticosteroids, calcineurin inhibitors, mTOR inhibitors, cyclophosphamide, azathioprine, mycophenolate, methotrexate Immunostimulation non-specific - levamizole, isoprinosine specific - vaccination substitution - immunoglobulins Therapy of allergic diseases Antihistamines used to treat allergic diseases 1. First generation Antihistaminics Highly sedative: Diphenhydramine, Dimenhydrinate, Promethazine, Hydroxyzine Moderately sedative: Pheniramine, Cyproheptadine, Meclizine, Buclizine, Cinnarazine Mild sedative: Chlorpheniramine, Dexchlorpehniramine, Dimethindene, Triprolidine… Only injectable antihistaminic in the Czech republik – Bisulepin (Dithiaden). 2. Second generation Antihistaminics Fexofenadine, Loratadine, Desloratadine, Cetrizine, Levocetrizine, Azelastine, Mizolastine, Rupatadine…. Sodium cromoglycate Derivative of Khellin, substance conained in corrot like plant Khella (Ammi visnaga), for centuries used as myorelaxans (Egypt). Stabilizes membrane of basophiles - prevents degranulation and release of mediators of allergic reaction. Acts „a step earlier“ than antihistamines. Application in nasal sprays, nebulizers, drops but also orally. Commercial preparations - local - Allergocrom, Cromohexal,
    [Show full text]
  • Pharmacological Research
    pharmacological research Editor Prof. Viktor BAUER, MD., DSc. Consulting Editors Michal DUBOVICKÝ, PhD. Assoc. Prof. Magda KOUŘILOVÁ, PhD. Mojmír MACH, PhD. Ja na NAVA ROVÁ, PhD. Prof. Radomír NOSÁĽ, MD., DSc. Ružena SOTNÍKOVÁ, PhD. entálnej f rim ar pe ma ex ko l v ó a g t i s e ú i n y s g t o i t l u o t c e a o m r f a e h x p p e l r a i t m n e BRATISLAVA 2008 Trends in Pharmacological Research ISBN 978–80–970003–7–0 Published by Institute of Experimental Pharmacology, SASc. Dúbravská cesta 9, SK-841 04 Bratislava, Slovak Republic fax: +421-2-59477 5928 • e-mail: [email protected] Printed in Slovak Republic Cover, Interior Design & Typesetting Mojmir Mach, PhD. Copyright © 2008 Institute of Experimental Pharmacology All rights reserved. No part may be reproduced, stored in a retrieval system, or trans- mitted in any form or by any means, electronic, mechanical, photocopying, recording, or ortherwise, without prior written permission from the Copyright owners. pharmacological research Table of Contents Editorial V. Bauer 7 Brief history of the Institute of Experimental Pharmacology R. Nosáľ 8 Trends in studies of drug metabolism and of related drug–drug interactions P. Anzenbacher, E. Anzenbacherová 11 Smooth muscle tissues as models for study of drug action V. Bauer, R. Sotníková, V. Nosáľová, J. Navarová, Š. Mátyás, V. Pucovský, V. Rekalov, K. Szőcs, J. Nedelčevová, Z. Kyseľová, V. Dytrichová, J. Fatyková, M. Kollárová, L. Máleková, M. Srnová, Z. Stojkovičová, G. Tóthová 15 New ways of supplementary and combinatory therapy of rheumatoid arthritis (RA) by synthetic and natural substances with antioxidant properties: New perspectives for routinely administered drugs in RA K.
    [Show full text]
  • Poison Or Antibiotic? a Guide to "Class" Entries
    Poison or Antibiotic? A Guide to “Class” Entries Preface Most entries in the Poisons List, i.e. the Schedule 10, and the Schedules 1, 2 and 3 to the Pharmacy and Poisons Regulations (Cap. 138A) are in the form of individual drugs and their salts, e.g. “Abacavir; its salts”. However, some entries are in the form of a “class”, e.g. “Barbituric acid; its salts; its derivatives …”. In such cases, it is not always clear which drugs are members of the class (e.g. amobarbital, barbital, pentobarbital, phenobarbital, etc. are poisons, being derivatives of barbituric acid). Likewise, the Antibiotics Ordinance (Cap. 137) applies to the substances specified in Schedule 1 to the Antibiotics Regulations, to their salts and derivatives, and to the salts of such derivatives. Again, it is not always clear which drugs are derivatives of an antibiotic named in the Schedule (e.g. demeclocycline, doxycycline, tigecycline, etc. are antibiotics, being derivatives of “Tetracycline” named in the Schedule). This Guide provides a list of such drugs which are available as registered pharmaceutical products in Hong Kong. Drugs which are not available as registered pharmaceutical products in Hong Kong are also included in this Guide as far as possible. It should be noted that it is not possible to compile a complete list of all these drugs, simply because there is no limit to the number of “derivatives” a parent chemical can have. This Guide should be read in conjunction with the Schedules 1, 2, 3, and 10 to the Pharmacy and Poisons Regulations, and Schedule 1 to the Antibiotics Regulations, if the poison/antibiotic classification of a particular pharmaceutical product is to be determined.
    [Show full text]
  • (Microsoft Powerpoint
    Antihistamines Histamine • is released from mast cells granules by exocytosis (activation of phospholipase C a ↑ Ca 2+ ) Stimuli : imunological: antigen + IgE physical , chemical or mechanical cell damage drugs Histamin receptors • 4 subtypes (H 1 –H4) • G protein-coupled receptors • their stimulation results in increase in cellular concentration of Ca 2+ ions H1 receptors • postsynaptic , Gq-protein ↑ phospholipase C → ↑ IP3 and DAG → ↑ Ca 2+ Lo cation : endothel , smooth muscles (vessels , bronchi , uterus, GIT), peripheral neuron ending, CNS (!!!) Effect : smooth muscle contraction (bronchi, uterus, ileum) vasodilatation of minor vessels (↓BP, reddening of skin) increase in vessel permeability ( swelling ) irritation of peripheral neuron endings (itching, even pain) excitation of CNS H2 receptors • postsynaptic , Gs-protein ↑ activity of adenylate cyclase → ↑cAMP Location: stomach mucosa , heart , vessels , immune system Effect : in stomach: gastric acid, pepsine, intrinsic factor secretion slower and longer vasodilatation + inotropic , + chronotropic effect H3 receptors 2+ • presynaptic , Gi protein → inhibition of N -type Ca channels → ↓ cellular Ca 2+ • feedback inhibition of histamine release • heterorec eptors , ↓ release of other neurotransmitters Location: mainly in CNS (but in PNS tissues as well ) Effect : sedation negative chronotropic effect bronchoconstriction H4 receptors • possibly isoform of H3 Location : • eosinophiles, basophiles, bone marrow, thymus, intestine , spleen Effect : – influencing activity of immune system
    [Show full text]
  • Modern Antihistamines in Treating Allergies: Current Trends in Symptomatic Therapy of Allergic Conditions Allergic Diseases Are a Serious Problem in Modern Medicine
    AKTUÁLNÍ FARMAKOTERAPIE MODERNÍ ANTIHISTAMINIKa v lÉčBě aLERGIe – SOUčASNÉ TRENDy v sYMPTOMATICKÉ TERAPII ALERGICKÝCH ONEMOCNěNÍ Moderní antihistaminika v léčbě alergie – současné trendy v symptomatické terapii alergických onemocnění Jaroslava Braunová, Mojmír Račanský Oddělení alergologie a klinické imunologie FNOL, Ústav imunologie UP Olomouc Alergická onemocnění jsou problémem současné medicíny. Nejde o pouhé projevy sezónní rýmy, s nimiž se do jisté míry setkal snad každý, ale také o závažné stavy, jako je anafylakticky šok a exacerbace bronchiálního astmatu. Nezanedbatelnou kapitolu tvoří problematika různých kožních projevů přecitlivělosti. Vždy však působí postiženému značné nepříjemnosti. Spolu s rostoucí incidencí těchto alergologických diagnóz pochopitelně stoupá i poptávka po jejich účinné léčbě. Za kauzální léčbu považujeme alergenovou imunoterapii (AIT). Ta však není indiko- vána pro všechny pacienty a všechny alergologické diagnózy. Vyžaduje vysokou compliance ze strany nemocného, přesné určení spouštěče alergické reakce u daného pacienta a existenci dostupného standardizovaného alergenu. Symptomatická terapie antihistaminiky představuje jednu ze zásadních možností ovlivnění rozvoje alergické reakce přímo na periferním histaminovém receptoru H1. Klíčová slova: alergie, symptomatická terapie, antihistaminika, alergický zánět. Modern antihistamines in treating allergies: current trends in symptomatic therapy of allergic conditions Allergic diseases are a serious problem in modern medicine. It is not only a question of pollinosis,
    [Show full text]
  • Moderní Antihistaminika V Léčbě Alergie – Současné Trendy V Symptomatické Terapii Alergických Onemocnění
    PŘEHLEDOVÉ ČLÁNKY MODERNÍ ANTIHISTAMINIKA V LÉčBě ALERGIE – SOUčASNÉ TRENDY V SYMPTOMATICKÉ TERAPII ALERGICKÝCH ONEMOCněNÍ Moderní antihistaminika v léčbě alergie – současné trendy v symptomatické terapii alergických onemocnění MUDr. Jaroslava Braunová, Ph.D., MUDr. Mojmír Račanský Oddělení alergologie a klinické imunologie fakultní nemocnice Olomouc, Ústav imunologie Univerzity Palackého Olomouc Alergická onemocnění jsou problémem současné medicíny. Nejde o pouhé projevy sezónní rýmy, s nimiž se do jisté míry setkal snad kaž- dý, ale také o závažné stavy, jako je anafylaktický šok a exacerbace bronchiálního astmatu. Nezanedbatelnou kapitolu tvoří problematika různých kožních projevů přecitlivělosti. Vždy však působí postiženému značné nepříjemnosti. Spolu s rostoucí incidencí těchto alergolo- gických diagnóz pochopitelně stoupá i poptávka po jejich účinné léčbě. Za kauzální léčbu považujeme alergenovou imunoterapii (AIT). Ta však není indikována pro všechny pacienty a všechny alergologické diagnózy. Vyžaduje vysokou compliance ze strany nemocného, přesné určení spouštěče alergické reakce u daného pacienta a existenci dostupného standardizovaného alergenu. Symptomatická terapie antihistaminiky představuje jednu ze zásadních možností ovlivnění rozvoje alergické reakce přímo na periferním histaminovém receptoru H1. Klíčová slova: alergie, symptomatická terapie, antihistaminika, alergický zánět. Modern antihistamines in treating allergies: current trends in symptomatic therapy of allergic conditions Allergic diseases are a challenge for contemporary medicine. They involve not only the mere manifestations of seasonal rhinitis, encountered to a certain degree by nearly everyone, but also serious conditions, such as anaphylactic shock and bronchial asthma exacerbation. A non-negligible aspect is the issue of various skin manifestations of hypersensitivity. They are invariably associat- ed with a great deal of discomfort for the sufferer. With a rising incidence of these allergic conditions, the demand for effective treatment naturally rises.
    [Show full text]
  • Současné Trendy V Léčbě a Diagnostice Chronické Nespavosti Souborný Článek
    Čes a slov Psychiat 2020; 116(3): 139–149 SOUčASNÉ TRENDY V LéčBě a diaGNOSTICE CHRONICKÉ NEspaVOSTI souborný článek David Kec1,2 Ondřej Ludka3,4 SOUHRN SUMMARY Veronika Hamerníková5 Jan Kubánek6 Kec D, Ludka O, Hamerníková V, Ku- Kec D, Ludka O, Hamerníková V, 1,2 Josef Bednařík bánek J, Bednařík J, Vlčková E. Součas- Kubánek J, Bednařík J, Vlčková E. Cur- Eva Vlčková1,2 né trendy v léčbě a diagnostice chro- rent trends in the treatment and diag- nické nespavosti nosis of chronic insomnia 1Lékařská fakulta MU v Brně 2Neurologická klinika FN Brno Přehledné sdělení shrnuje aktuální mož- The review summarizes the current 3I. interní kardio-angiologická nosti diagnostiky a léčby chronické ne- possibilities of diagnosis and treat- klinika FN u sv. Anny v Brně spavosti a reflektuje specifika českého ment of chronic insomnia and reflects 4Mezinárodní centrum klinického prostředí (dostupnost jednotlivých léků, the specifics of the Czech environment výzkumu FN u sv. Anny v Brně možnosti kognitivně-behaviorální tera- (the availability of individual drugs, 5Odborný psycholog, pie). Vychází z recentně aktualizovaných possibilities of cognitive-behavioral Opletalova 600/6, Brno mezinárodních klinických doporučení therapy). It is based on recently updat- 6Psychiatr v Priessnitzových v oblasti somnologie i doporučení od- ed international clinical recommenda- léčebných lázních, Jeseník borných společností České lékařské spo- tions in the field of somnology (Euro- lečnosti Jana Evangelisty Purkyně. pean Sleep Research Society, American Kontaktní adresa: Doporučené postupy Evropské spo- Academy of Sleep Medicine) as well prof. MUDr. Ondřej Ludka, Ph.D. lečnosti pro výzkum spánku (European as on the recommendations of profes- I. interní kardio-angiologická klinika Sleep Research Society), Americké aka- sional societies of the Czech Medical FN u sv.
    [Show full text]